Get the Stockscreener App
6.12
17.63%
-1.31
After Hours:
6.15
0.03
+0.49%
Vanda Pharmaceuticals Inc stock is traded at $6.12, with a volume of 3.43M.
It is down -17.63% in the last 24 hours and down -17.41% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$7.43
Open:
$7.15
24h Volume:
3.43M
Relative Volume:
2.10
Market Cap:
$361.67M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
116.79
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-15.35%
1M Performance:
-17.41%
6M Performance:
+42.00%
1Y Performance:
+28.84%
1-Day Range:
$6.005
$7.15
1-Week Range:
$6.005
$7.72
52-Week Range:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.12 | 439.09M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
Vanda Pharmaceuticals’ stock tumbles after $220M loss - The Business Journals
Vanda Pharmaceuticals Inc files for mixed shelf offering of up to $200 millionSEC filing - marketscreener.com
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Vanda declines on Q4 results, weak 2026 revenue guidance - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc Files For Mixed Shelf Offering Of Upto $200 MillionSEC Filing - TradingView
Vanda Pharmaceuticals Inc. SEC 10-K Report - TradingView
Vanda Pharmaceuticals (VNDA) Eyes Growth Amidst Strong Prescription Sales and Pipeline Expansion - GuruFocus
Vanda (VNDA) Q4 2025 Earnings Call Transcript - AOL.com
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Plummets 9.8% After Mixed Q4 2025 Earnings Report - ChartMill
Earnings call transcript: Vanda Pharmaceuticals Misses Q4 2025 Expectations By Investing.com - Investing.com India
Vanda Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda: Q4 Financial Results Overview - Bitget
Vanda Pharmaceuticals (VNDA) Projects Lower FY26 Revenue Than Ex - GuruFocus
Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results, Beats Expectations By $0.99 EPS - MarketBeat
Vanda: Q4 Earnings Snapshot - marketscreener.com
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
Vanda Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Analyst Downgrade: Will Vanda Pharmaceuticals Inc outperform tech stocksJuly 2025 Volume & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Thursday - MarketBeat
ETF Watch: Is Vanda Pharmaceuticals Inc stock a good pick for beginnersJuly 2025 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 23.3% in January - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Vanda Pharmaceuticals, The New York Islanders New Jersey Sponsor - Yahoo Sports Canada
Take Profit: Can Vanda Pharmaceuticals Inc ride the EV wavePrice Action & Low Volatility Stock Suggestions - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (VNDA): Investor Outlook Reveals 77% Potential Upside - DirectorsTalk Interviews
Can Bysanti Redefine Vanda's Commercial Portfolio? - RTTNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - Chartmill
Earnings Report: Can Vanda Pharmaceuticals Inc ride the EV waveForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - FinancialContent
Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application - MSN
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc - GuruFocus
VNDA: Imminent launches and label expansions position the portfolio for major near-term growth - TradingView — Track All Markets
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation - marketscreener.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 52.3% in December - MarketBeat
Loss Report: How Vanda Pharmaceuticals Inc stock benefits from tech adoptionShort Setup & Weekly High Potential Alerts - Bộ Nội Vụ
Revenue Check: Why Vanda Pharmaceuticals Inc stock remains a top recommendationPortfolio Gains Summary & Fast Gain Stock Tips - Bộ Nội Vụ
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Retail Trends: Will Vanda Pharmaceuticals Inc stock attract more institutional investorsProfit Target & Technical Confirmation Trade Alerts - Bộ Nội Vụ
Aug Retail: Why Vanda Pharmaceuticals Inc stock remains a top recommendation2025 Technical Overview & Weekly Consistent Profit Watchlists - Bộ Nội Vụ
Published on: 2026-01-12 16:11:40 - Улправда
What sentiment indicators say about Vanda Pharmaceuticals Inc. stockMarket Sentiment Summary & Weekly High Potential Stock Alerts - Улправда
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - Sahm
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):